Iguratimod Methotrexate Combination Therapy for Rheumatoid Arthritis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for arthritic diseases, particularly rheumatoid arthritis, are limited in effectively suppressing joint and bone destruction and are associated with significant adverse reactions, including hepatocellular damage from immunosuppressive agents like methotrexate.
Innovation Solution
A pharmaceutical composition combining iguratimod or its pharmacologically acceptable salt with methotrexate, which reduces adverse reactions and enhances therapeutic effects, allowing for continued therapy while minimizing hepatocellular damage, and can be administered with various pharmaceutically acceptable additives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive agents like methotrexate are used to treat rheumatoid arthritis, then therapeutic effects are achieved, but hepatocellular damage occurs as an adverse reaction
Solution Approach 1:
The patent combines iguratimod and methotrexate into a single pharmaceutical composition for simultaneous administration. This merging of two drugs with different mechanisms of action allows the methotrexate to provide immunosuppressive therapy while iguratimod mitigates its hepatotoxic effects, resolving the contradiction between therapeutic efficacy and liver damage
Solution Approach 2:
Iguratimod acts as a protective intermediary that reduces the harmful impact of methotrexate on liver cells. The patent describes this combination where iguratimod serves as a mediator that allows continued use of methotrexate therapy while protecting against its adverse hepatocellular effects
2Duration of action of stationary object
If DMARDs and immunosuppressive agents are used from early stage to suppress autoimmune response, then progression of joint and bone destruction is slowed, but long-term use becomes difficult due to adverse reactions
Solution Approach 1:
The patent merges iguratimod with methotrexate or other DMARDs to create a combination therapy that maintains long-term disease control while reducing adverse reactions. This combined approach enables continued treatment beyond the limitations imposed by single-agent toxicity
Solution Approach 2:
The patent changes the therapeutic parameters by introducing a second active ingredient that modifies the overall safety profile of the regimen. This parameter change allows extension of treatment duration by altering the toxicity characteristics of the therapy
3Reliability
If combined use of iguratimod and methotrexate is employed, then therapeutic effects are potentiated, but drug complexity increases
Solution Approach 1:
The patent merges two drugs into a single combined pharmaceutical composition, which simplifies administration compared to separate dosing regimens. This merging approach maintains the therapeutic benefits of both agents while reducing the complexity of patient compliance
Solution Approach 2:
The combined pharmaceutical composition serves multiple functions simultaneously: providing immunosuppressive therapy from methotrexate and hepatoprotective effects from iguratimod. This multi-functionality reduces the need for multiple separate medications and simplifies the overall treatment regimen
Data Source
AI summary
In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases. This method and pharmaceutical composition are useful for the treatment of more severe autoimmune diseases.